Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $16.80

Replimune Group, Inc. (NASDAQ:REPL) has received an average rating of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $16.80.

A number of research firms have recently commented on REPL. JPMorgan Chase & Co. increased their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm started coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research note on Tuesday.

Replimune Group Price Performance

REPL stock opened at $11.40 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The firm has a market capitalization of $778.86 million, a P/E ratio of -3.75 and a beta of 1.19. The business’s 50-day moving average is $11.44 and its two-hundred day moving average is $9.50. Replimune Group has a 1 year low of $4.92 and a 1 year high of $12.97.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Analysts anticipate that Replimune Group will post -3.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of REPL. SG Americas Securities LLC acquired a new position in Replimune Group in the first quarter valued at $147,000. Russell Investments Group Ltd. acquired a new position in Replimune Group in the first quarter valued at $140,000. Entropy Technologies LP increased its stake in Replimune Group by 18.3% in the first quarter. Entropy Technologies LP now owns 59,326 shares of the company’s stock valued at $485,000 after purchasing an additional 9,180 shares during the last quarter. Vanguard Group Inc. increased its stake in Replimune Group by 1.2% in the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after purchasing an additional 32,555 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Replimune Group in the first quarter valued at $927,000. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.